

Carfilzomib (56mg/m² once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 dayⁱ

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Carfilzomib, lenalidomide and dexamethasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy	C90	00598a	ODMS

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Table 1: Carfilzomib in combination with lenalidomide and dexamethasone

DRUG	CYCLE 1							
	Week 1		Week 2		Week 3		Week 4	
	Day 1	Days 2-7	Day 8	Days 9-14	Day 15	Days 16-21	Day 22	Days 23-28
Carfilzomib (mg/m ²) ^{a,b}	20		56		56			
Dex (mg) ^c	40		40		40		40	
Lenalidomide ^d	25mg daily						Rest	Rest
DRUG	CYCLE 2-9							
	Week 1		Week 2		Week 3		Week 4	
	Day 1	Days 2-7	Day 8	Days 9-14	Day 15	Days 16-21	Day 22	Days 23-28
Carfilzomib (mg/m ²) ^{a,b}	56		56		56			
Dex (mg) ^c	40		40		40		40	
Lenalidomide ^d	25mg daily						Rest	Rest
DRUG	CYCLE 10 -12							
	Week 1		Week 2		Week 3		Week 4	
	Day 1	Days 2-7	Day 8	Days 9-14	Day 15	Days 16-21	Days 22-28	
Carfilzomib (mg/m ²) ^{a,b}	56		56		56			
Dex (mg) ^c	40		40		40			
Lenalidomide ^d	25mg daily						Rest	
DRUG	CYCLE 13 onwards							
	Week 1		Week 2		Week 3		Week 4	
	Day 1	Days 2-7	Day 8	Days 9-14	Day 15	Days 16-21	Days 22-28	
Carfilzomib (mg/m ²) ^{a,b}	56				56			
Dex (mg) ^c	40		40		40			
Lenalidomide ^d	25mg daily						Rest	

^aInfusion time for first infusion of 20mg/m² is 30 minutes and then subsequent infusions of 56mg/m² are administered over 30 minutes. See table 2 for details

^bPatients with a BSA greater than 2.2 m² should receive a dose based upon a BSA of 2.2 m². Dose adjustments do not need to be made for weight changes of less than or equal to 20%.

^cDexamethasone should be administered 30 minutes to four hours before carfilzomib.

^dConsider appropriate dose reduction for the starting dose of lenalidomide according to current lenalidomide summary of product characteristics. This is especially important for patients with baseline renal impairment in whom excessive myelosuppression due to

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRd)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 1 of 10

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

lenalidomide may occur

- When combined with lenalidomide and dexamethasone, carfilzomib is administered on day 1,8 and 15 of a 28 day treatment cycle as shown in table 1.
- Carfilzomib is administered at a starting dose of 20 mg/m² (maximum dose 44 mg), in cycle 1 on day 1.
- If tolerated, the dose should be increased on day 8 of cycle 1 to 56 mg/m² (maximum dose 123 mg).
- From cycle 10 onwards, dexamethasone is administered on days 1, 8 and 15 only (day 22 dose of dexamethasone is omitted)
- From cycle 13, carfilzomib is administered on days 1 and 15 only (day 8 dose is omitted).
- Treatment may be continued for up to 18 cycles or until disease progression or unacceptable toxicity occurs.

Administration guidelines:

Dexamethasone and lenalidomide are both administered orally.

Carfilzomib is administered as detailed in table 2 below.

Table 2: Administration details for carfilzomib

Cycle	Day	Drug	Dose	Route	Diluent and Rate
1	1	Carfilzomib	^a 20mg/m ²	IV infusion	100ml Glucose 5% ^c over 30 mins
1	8, 15	Carfilzomib	^b 56mg/m ²	IV infusion	100ml Glucose 5% ^c over 30 mins
^a Maximum dose of carfilzomib is 44mg					
^b Maximum dose of carfilzomib is 123mg					
^c Carfilzomib may be administered in 50-100ml Glucose 5%					
Carfilzomib is a proteasome inhibitor and is neurotoxic. Refer to NCCP Guidance on the Safe Use of Neurotoxic drugs (including Vinca Alkaloids) in the treatment of cancer. Available Here					

ELIGIBILITY:

- Indication as above
- ECOG 0-2

EXCLUSIONS:

- Hypersensitivity to carfilzomib, lenalidomide or any of the excipients.
- Pregnancy.
- Breastfeeding
- Women of childbearing potential unless all the conditions of the Revlimid® Pregnancy Prevention Programme are met.

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Haematologist working in the area of haematological malignancies.

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRD)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 2 of 10

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

TESTS:

Baseline tests:

- FBC, renal, liver and bone profile
- Blood pressure, blood glucose (patients on oral hypoglycaemics)
- Assessment of peripheral neuropathy status
- VTE risk assessment
- Pregnancy test in women of child-bearing age or evidence of a hysterectomy. Assessment and registration as per Pregnancy Prevention Program for both male and female patients.
- Virology screen -Hepatitis B (HBsAg, HBcoreAb), Hepatitis C, HIV.

***See Adverse Effects/Regimen Specific Complications re Hepatitis B Reactivation**

Regular tests:

- FBC, renal and liver profile monthly.
- Blood pressure, *blood glucose if being treated with oral hypoglycaemics. (* See Drug Interactions)
- Pregnancy test every 28 days if female of childbearing potential.
- Consider monitoring thyroid function tests.

Disease monitoring:

Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant
- Dose adjustments of carfilzomib do not need to be made for weight changes of less than or equal to 20% subject to local policy.
- Lenalidomide treatment must not be started if the ANC is < 1x 10⁹/L and/or platelets < 75 x 10⁹/L or dependent on bone marrow infiltration by plasma cells, platelet counts < 30 x 10⁹/L
- Dose level reductions for carfilzomib and lenalidomide are described in Table 3 below

Treatment guidelines for specific hematologic toxicities (thrombocytopenia and neutropenia) are outlined in Tables 4 and 5.

Table 3: Dose Level Reductions for Carfilzomib and Lenalidomide

	Carfilzomib	Lenalidomide
Starting Dose	56 mg/m²	25mg
Dose level -1	45 mg/m ²	20mg
Dose level -2	36 mg/m ²	15mg
Dose level- 3	27 mg/m ²	10mg
Dose level-4	Discontinue carfilzomib	5mg
Dose level-5		2.5mg

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRD)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 3 of 10

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Haematological:

Table 4: Dose Modifications for Thrombocytopenia

Platelets	Lenalidomide	Platelets	Carfilzomib
Fall to < 30 x 10 ⁹ /L	Hold lenalidomide therapy, follow FBC weekly. Hold prophylactic anticoagulation until platelets return to ≥30x10 ⁹ /L then resume at 1 dose decrement	If 10-30 x 10 ⁹ /L without evidence of bleeding	Maintain full dose
		If < 10 x 10 ⁹ /L or evidence of bleeding	Hold dose until platelets return to ≥ 10 x 10 ⁹ /L and/or bleeding is controlled then resume at same dose level
For each subsequent drop to < 30 x 10 ⁹ /L	Hold lenalidomide therapy, follow FBC weekly. Hold prophylactic anticoagulation until platelets return to ≥30x10 ⁹ /L then resume at additional dose decrement. Do not dose below 5mg once daily	If 10-30 x 10 ⁹ /L without evidence of bleeding	Maintain full dose
		If < 10 x 10 ⁹ /L or evidence of bleeding	Hold dose until platelets return to ≥ 10 x 10 ⁹ /L and/or bleeding is controlled, then consider 1 dose level reduction when restarting carfilzomib.

Table 5: Dose Modifications for Neutropenia

ANC	Lenalidomide	ANC	Carfilzomib
Falls to < 1.0 x 10 ⁹ /L	Hold lenalidomide therapy, administer G-CSF, follow FBC weekly; then resume at full dose when ANC ≥ 1.0x10 ⁹ /L	0.5-1.0 x 10 ⁹ /L	Maintain full dose
		< 0.5 x 10 ⁹ /L	Hold dose Resume at full dose when ANC ≥ 0.5 x 10 ⁹ /L
For each subsequent drop to <1.0 x 10 ⁹ /L	Hold lenalidomide therapy, administer G-CSF, follow FBC weekly; then resume at 1 dose decrement when ANC ≥ 1.0x10 ⁹ /L	0.5-1.0 x 10 ⁹ /L	Maintain full dose
		For subsequent drops to < 0.5 x 10 ⁹ /L	Hold dose Resume when ANC ≥ 0.5 x 10 ⁹ /L and consider 1 dose level reduction
		Febrile neutropenia ANC < 0.5 x 10 ⁹ /L and an oral temperature > 38.5 ⁰ C or two consecutive readings of > 38.0 ⁰ C for 2 hours	Hold dose If ANC returns to baseline grade and fever resolves, resume at same dose level
In the case of neutropenia, the use of growth factors in patient management should be considered			

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRD)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 4 of 10
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Renal and Hepatic Impairment:

Table 6: Dose modification of carfilzomib and lenalidomide based on renal function

Carfilzomib	<ul style="list-style-type: none"> No starting dose adjustment for carfilzomib is required in patients with baseline mild, moderate, or severe renal impairment or patients on chronic dialysis. Renal function should be monitored, particularly in patients with lower baseline creatinine clearance (CrCL < 30 mL/min). If Serum creatinine $\geq 2 \times$ baseline or if Creatinine clearance < 15 mL/min (or creatinine clearance decreases to $\leq 50\%$ of baseline) or need for dialysis, stop dose and continue monitoring renal function (serum creatinine or creatinine clearance). Carfilzomib should be resumed when renal function has recovered to within 25% of baseline; consider resuming at 1 dose level reduction. Since dialysis clearance of carfilzomib concentrations has not been studied, the medicinal product should be administered after the dialysis procedure. There are limited efficacy and safety data on patients with baseline creatinine clearance < 30 mL/min. 										
	Lenalidomide	<table border="1"> <thead> <tr> <th>Creatinine Clearance ml/min</th> <th>Dose modification</th> </tr> </thead> <tbody> <tr> <td>30 to 50</td> <td>Reduce dose to 10mg once daily*</td> </tr> <tr> <td><30 not requiring dialysis</td> <td>15mg every other day</td> </tr> <tr> <td>< 30 requiring dialysis</td> <td>Reduce dose to 5mg once daily. On dialysis days dose should be administered after dialysis.</td> </tr> <tr> <td colspan="2">*The dose may be escalated to 15mg once daily after 2 cycles if patient is not responding to treatment and is tolerating the treatment</td> </tr> </tbody> </table>	Creatinine Clearance ml/min	Dose modification	30 to 50	Reduce dose to 10mg once daily*	<30 not requiring dialysis	15mg every other day	< 30 requiring dialysis	Reduce dose to 5mg once daily. On dialysis days dose should be administered after dialysis.	*The dose may be escalated to 15mg once daily after 2 cycles if patient is not responding to treatment and is tolerating the treatment
Creatinine Clearance ml/min	Dose modification										
30 to 50	Reduce dose to 10mg once daily*										
<30 not requiring dialysis	15mg every other day										
< 30 requiring dialysis	Reduce dose to 5mg once daily. On dialysis days dose should be administered after dialysis.										
*The dose may be escalated to 15mg once daily after 2 cycles if patient is not responding to treatment and is tolerating the treatment											

Hepatic impairment:

Table 7: Dose modification of carfilzomib and lenalidomide based on hepatic function

Carfilzomib	<ul style="list-style-type: none"> No starting dose adjustment is recommended in patients with mild or moderate hepatic impairment based on available pharmacokinetic data. However, higher subject incidence of hepatic function abnormalities, \geq grade 3 adverse events and serious adverse events have been reported in patients with mild or moderate baseline hepatic impairment compared with patients with normal hepatic function. Liver enzymes and bilirubin should be assessed at treatment initiation and monitored monthly during treatment with carfilzomib, regardless of baseline values, and appropriate dose modifications based on toxicity should be made
Lenalidomide	<ul style="list-style-type: none"> Lenalidomide has not formally been studied in patients with impaired hepatic function and there are no specific dose recommendations

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRD)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 5 of 10
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Management of adverse events

Table 8: Dose modifications for non-haematological toxicity for carfilzomib

Adverse Event	Carfilzomib
<p>Non-haematologic toxicity (renal) Serum creatinine $\geq 2 \times$ baseline;</p> <p>OR</p> <p>Creatinine clearance < 15 mL/min (or creatinine clearance decreases to $\leq 50\%$ of baseline) or need for dialysis</p>	<p>Hold dose and continue monitoring renal function (serum creatinine or creatinine clearance)</p> <p>Carfilzomib should be resumed when renal function has recovered to within 25% of baseline; consider resuming at 1 dose level reduction^a</p> <p>For patients on dialysis receiving carfilzomib, the dose is to be administered after the dialysis procedure</p>
<p>All other grade 3 or 4 non-haematologic toxicities</p>	<p>Stop carfilzomib until resolved or returned to baseline. Consider restarting the next scheduled treatment at 1 dose level reduction</p>
<p>^a see table 3 for dose level reductions</p>	

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Low (Refer to local policy).

PRE-MEDICATIONS:

- Adequate hydration is required before dose administration in cycle 1, especially in patients at high risk of tumour lysis syndrome or renal toxicity
- All patients should be monitored for evidence of volume overload and fluid requirements should be tailored to individual patient needs
- The total volume of fluids may be adjusted as clinically indicated in patients with baseline cardiac failure or who are at risk for cardiac failure
- Recommended hydration includes both
 - oral fluids (30 mL/kg/day for 48 hours before day 1 of cycle 1) and
 - intravenous fluids (250 mL to 500 mL of appropriate intravenous fluid before each dose in cycle 1).
 - Give an additional 250 mL to 500 mL of intravenous fluids as needed following carfilzomib administration in cycle 1
- Oral and/or intravenous hydration should be continued, as needed, in subsequent cycles.
- Serum potassium levels should be monitored monthly or more frequently during treatment with carfilzomib as clinically indicated. The frequency of assessment will depend on the potassium levels measured before the start of treatment, concomitant therapy used (e.g. medicinal products known to increase the risk of hypokalaemia) and associated comorbidities
- Ensure patient remains well hydrated during treatment

OTHER SUPPORTIVE CARE:

- Antiviral prophylaxis should be considered in patients being treated with carfilzomib to decrease the risk of herpes zoster reactivation (**Refer to local policy**)
- Tumour Lysis Syndrome (TLS) has been reported in patients receiving carfilzomib. As well as adequate prophylaxis, consider prophylactic treatment e.g. allopurinol (**Refer to local policy**)

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRD)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 6 of 10

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

- Thromboprophylaxis (**Refer to local policy**)
- In case of neutropenia the consultant may consider the use of filgrastim (G-CSF)
- Prophylactic laxatives to prevent lenalidomide-induced constipation (**Refer to local policy**).
- Bisphosphonates should be considered in all patients with myeloma-related bone disease.
- Consider the use of a H₂ antagonist or proton pump inhibitor if appropriate in patients receiving dexamethasone therapy (**Refer to local policy**).

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

Carfilzomib is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.

Carfilzomib

- **Cardiovascular:** New or worsening cardiac failure (e.g. congestive cardiac failure, pulmonary oedema, decreased ejection fraction), myocardial ischaemia and infarction have occurred following administration of carfilzomib. While adequate hydration is required prior to dosing in cycle 1, all patients should be monitored for evidence of volume overload, especially patients at risk for cardiac failure. The total volume of fluids may be adjusted as clinically indicated in patients with baseline cardiac failure or who are at risk for cardiac failure. Stop carfilzomib for grade 3 or 4 cardiac events until recovery and consider whether to restart carfilzomib at 1 dose level reduction based on a benefit/risk assessment.

The risk of cardiac failure is increased in elderly patients (≥ 75 years). Patients with signs or symptoms of NYHA Class III or IV cardiac failure, recent history of myocardial infarction (in the last 4 months), and in patients with uncontrolled angina or arrhythmias, should have a comprehensive medical assessment, prior to starting treatment with carfilzomib. This assessment should optimise the patient's status, with particular attention to blood pressure and fluid management. Subsequently patients should be treated with caution and remain under close follow-up.

- **Electrocardiographic changes:** There have been cases of QT interval prolongation reported in clinical studies with carfilzomib. An effect of carfilzomib on QT interval cannot be excluded.
- **Pulmonary toxicity:** Acute respiratory distress syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in patients receiving carfilzomib. Some of these events have been fatal. Evaluate and stop carfilzomib until resolved and consider whether to restart carfilzomib based on a benefit/risk assessment.
- **Hypertension:** Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with carfilzomib. Some of these events have been fatal. It is recommended to control hypertension prior to starting treatment. All patients should be routinely evaluated for hypertension while on carfilzomib and treated as needed. If the hypertension cannot be controlled, the carfilzomib dose should be reduced. In case of hypertensive crises, stop carfilzomib until resolved or returned to baseline and consider whether to restart carfilzomib based on a benefit/risk assessment.
- **Infusion reactions:** Infusion reactions, including life-threatening reactions, have been reported in patients who received carfilzomib. These reactions can occur immediately following or up to 24 hours after administration of carfilzomib. Dexamethasone should be administered prior to carfilzomib to reduce the incidence and severity of reactions.
- **Hepatitis B Reactivation:** Patients should be tested for both HBsAg and HBcoreAb as per local policy. If either test is positive, such patients should be treated with anti-viral therapy, for the entire duration of chemotherapy and for six months afterwards (Refer to local policy). Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRD)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 7 of 10

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to stopping chemotherapy.

Lenalidomide

- **Teratogenic effects:** Lenalidomide is structurally related to thalidomide a powerful human teratogen. It must never be used by women who are pregnant or by women who could become pregnant unless all the conditions of the Revlimid® Pregnancy Prevention Programme are met.
- **Skin reactions:** Lenalidomide must be discontinued permanently for exfoliative or bullous rash or if Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) is suspected.
- **Cardiovascular:** Patients with known risk factors for MI, including prior thrombosis should be closely monitored and action should be taken to try to minimise all modifiable risk factors (e.g. smoking, hypertension and hyperlipidaemia). There is an increased risk of venous and arterial thromboembolism in patients treated with lenalidomide and dexamethasone. Previous history of thromboembolic events or concomitant administration of erythropoietic agents or other agents such as hormone replacement therapy, may also increase thromboembolic risk in these patients. Particularly, a haemoglobin concentration above 12g/dl should lead to discontinuation of erythropoietic agents. Thromboprophylaxis should be considered especially in patients with additional thrombotic risk factors.
- **Peripheral Neuropathy:** Lenalidomide is structurally related to thalidomide which is known to induce severe peripheral neuropathy. The neurotoxic potential of lenalidomide associated with long-term use cannot be ruled out.
- **Thyroid function:** Cases of hypothyroidism have been reported and baseline and ongoing monitoring of thyroid function is recommended.
- **Tumour lysis syndrome:** Patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.

DRUG INTERACTIONS:

- Carfilzomib is primarily metabolised via peptidase and epoxide hydrolase activities, and as a result, the pharmacokinetic profile of carfilzomib is unlikely to be affected by concomitant administration of cytochrome P450 inhibitors and inducers.
- Erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone
- There is an increased risk of rhabdomyolysis when statins are administered with lenalidomide, which may be simply additive. Enhanced clinical and laboratory monitoring is warranted notably during the first weeks of treatment.
- Current drug interaction databases should be consulted for more information.

ATC CODE:

Carfilzomib - L01XX45
 Lenalidomide - L04AX04

COMPANY SUPPORT RESOURCES/Useful Links:

Please note that this is for information only and does not constitute endorsement by the NCCP

http://celgene.co.uk/content/uploads/sites/3/Revlimid_Prescription_Authorisation_Form.pdf

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRD)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 8 of 10

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

REFERENCES:

1. NCCP SACT Plasma Cell Disorder Clinical Advisory Group: Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: Evidence into practice –rapid review March 2020
2. Leleu et al. Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma. Clinical lymphoma, myeloma and leukemia. Abstract only: Volume 19, Issue 10, Supplement E266-E267, October 2019
3. Biran et al. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. Am J Hematol. 2019;94:794–802
4. Moreau et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 2018;19: 953–64
5. Richez V, Gruchet C, Guidez S et al. Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma. Am J Hematol 2019;94(1): E17-E20.
6. Dimopoulos et al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. Journal of Hematology & Oncology (2018) 11:49
7. Keith Stewart A et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med 2015;372:142-52
8. Kyprolis® Summary of Product Characteristics Accessed March 2020. Available at https://www.ema.europa.eu/en/documents/product-information/kyprolis-epar-product-information_en.pdf Product Information/human/003790/WC500197692.pdf
9. Revlimid® Summary of Product Characteristics Accessed March 2020. Available at https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf

Version	Date	Amendment	Approved By
1	06/04/2020		Prof Paul Browne
2	14/04/2020	Clarification of carfilzomib dosing schedule from cycle 13 onwards	Prof Paul Browne
3	30/07/2020	Update of carfilzomib infusion time	Plasma Cell Disorder CAG

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ⁱ The administration of carfilzomib 56mg/m² once weekly in combination with lenalidomide is an unlicensed dosing posology for this indication in Ireland. Patient's should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or "off label" indications. Prescribers should be fully aware of their responsibility in communicating any relevant information to the

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRd)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 9 of 10

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

patient and also ensuring that the unlicensed or “off label” means of administration has been acknowledged by the hospital’s Drugs and Therapeutics Committee, or equivalent, in line with hospital policy

NCCP Regimen: Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone -28 day (KRD)	Published: 06/04/2020 Review: 06/04/2021	Version number: 3
Tumour Group: Myeloma NCCP Regimen Code: 00598	IHS Contributors: NCCP Plasma Cell Disorder CAG	Page 10 of 10
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		